The estimated Net Worth of Edward A. Neff is at least $126 ezer dollars as of 19 October 2016. Edward Neff owns over 227,272 units of Biocept Inc stock worth over $126,006 and over the last 11 years Edward sold BIOC stock worth over $0.
Edward has made over 3 trades of the Biocept Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Edward bought 227,272 units of BIOC stock worth $249,999 on 19 October 2016.
The largest trade Edward's ever made was buying 227,272 units of Biocept Inc stock on 19 October 2016 worth over $249,999. On average, Edward trades about 40,808 units every 68 days since 2014. As of 19 October 2016 Edward still owns at least 289,735 units of Biocept Inc stock.
You can see the complete history of Edward Neff stock trades at the bottom of the page.
Edward's mailing address filed with the SEC is 5810 Nancy Ridge Dr # 150, San Diego, CA 92121, USA.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff és David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: